ERBB2 and breast carcinoma: So far, the therapeutic strategies for treatment of breast cancer caused by her2 overexpression include using antibodies such as Herceptin® to block her2 protein ligand binding6 and chaperone Hsp90 antagonists to prevent stabilization of the active her2 conformation at the cell surface7,8.